Effective January 1, 2017, Independence will update its
list of specialty drugs that require member cost-sharing
(e.g., copayment, deductible, and coinsurance). Cost-sharing
applies to select medical benefit specialty drugs
for members who are enrolled in Commercial FLEX
products and other select plans. The member?s cost-sharing
amount is based on the terms of the member?s
benefit contract. Individual benefits should be verified.
The updated list will include approximately 130 drugs,
including new additions for Cinqair® (reslizumab),
InflectraTM (infliximab)*, Nucala® (mepolizumab), and
Probuphine® (buprenorphine).
The updated list is available on our website. The current 2016
cost-sharing list can be accessed through this link until
December 31, 2016.
Look for more information on medical benefit specialty
drug cost-sharing in the December 2016 edition of
Partners in Health UpdateSM.
* For members enrolled in Commercial FLEX products,
cost-sharing
applies to all biosimilars of infliximab approved by the U.S. Food and
Drug Administration.